DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

Biosimilars Advisory Service: Physician Perspectives on G-CSFs and Monoclonal Antibodies in Oncology

Five years after the first European approval of biosimilar filgrastim and six years after the European approval of biosimilar epoetin alfa, European oncologists have had comparatively high exposure to biosimilars. Biosimilar filgrastim molecules have been relatively successful penetrating the oncology market in Europe, but a significantly more commercially lucrative opportunity lies in the development of biosimilar monoclonal antibodies (MAbs). Roche’s hugely successful portfolio of MAbs provides a highly attractive target for biosimilar developers, and, unsurprisingly, the pipeline is rich with biosimilar rituximab, trastuzumab, and bevacizumab projects. Nevertheless, a major threat to biosimilar developers is the advent of new, improved biologics, which could supersede current standards of care, thereby reducing the opportunity available to biosimilar versions of currently prescribed biologics.

We surveyed 183 oncologists in the United States and Europe to gain insights into key topics affecting biosimilar and brand biologics across multiple indications and drug classes in oncology. Our primary market research explores medical oncologists’ and hematologist-oncologists’ familiarity with, and perception of, biosimilars, as well as other key topics pertinent to the biosimilar sector, such as pricing, reimbursement, automatic substitution, indication extrapolation, and the threat from “biobetters.” We provide in-depth primary market research and analysis of various granulocyte colony-stimulating factors (G-CSFs), erythropoiesis-stimulating agents (ESAs), and several MAbs. Our primary research helps inform our market forecasts for brand biologics and biosimilars in oncology markets across the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan).

This oncology-focused report is part of the Biosimilars Advisory Service. This service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilar space. Quarterly Webinars detailing major developments, analyst insight addressing key market changes, therapeutic area-specific primary research, and forecasting modules are all included in a subscription to the Biosimilars Advisory Service. Rely on BioTrends to keep you up to date on the biosimilars landscape and poised to maximize opportunities for your business.

Questions Answered in This Report:

  • Understand medical oncologists’ and hematologist-oncologists’ attitudes toward biosimilars. How aware are medical oncologists and hematologist-oncologists of biosimilars? How similar are biosimilars and brands according to both of these specialist groups? What are the greatest hurdles for uptake of biosimilar versions of these agents? What level of clinical trial data will convince specialists that biosimilars and brands are comparable? What are physician opinions of indication extrapolation and pharmacy-level substitution?

  • Understand how medical oncologists’ and hematologist-oncologists’ attitudes translate to expected use of biosimilars: How quickly do oncologists expect to adopt biosimilars? How will price affect oncologists’ uptake of biosimilars? To what extent will cross-brand erosion from biosimilars occur?

  • Forecast the anticipated uptake of biosimilar versions of G-CSFs and MAbs: What is the expected patient share of biosimilar versions of major biologics prescribed in oncology? At what price discounts will biosimilars for different brands enter the market, and how might this change? What is the annualized commercial potential of biosimilar versions of major biologics prescribed in oncology? Will biosimilars steal a majority or minority market share?


This report is based on a quantitative survey of 183 oncologists (90 medical oncologists and 93 hematologist-oncologists) in the United States, France, and Germany.

Markets covered: United States, Europe, and Japan.

Primary research: Quantitative 45-minute online survey of 90 medical oncologists and 93 hematologist-oncologists in the United States, France, and Germany.

To qualify for participation, surveyed specialists had to meet the following criteria:

- Have worked in clinical practice for a minimum of 3 years and a maximum of 30 years.

- Work for a community hospital, private practice, or academic hospital (defined as having a large teaching facility).

- Spend more than 50% of their professional time in clinical practice if associated with an academic hospital or 75% of their professional time if based in a community hospital or private practice.

- Be familiar with the major biologics (MAbs, G-CSFs, and ESAs) prescribed in oncology indications.

Related 2013 Reports:

- Biosimilars Advisory Service: Corporate Strategies

- Biosimilars Advisory Service: Global Pipelines, Pathways, and Key Stakeholder Perceptions

- Biosimilars Advisory Service: Overall Physicians

- Biosimilars Advisory Service: US and EU Payer Perspectives

- Biosimilars Advisory Service: Immunology and Infectious Diseases

- Biosimilars Advisory Service: Endocrinology and Nephrology